H1N1 vaccines pulled due to severe reaction fears

awake

http://www.examiner.com/x-29675- ... vere-reaction-fears
* H& M5 x/ Y# J; ]! K4 P) Z
4 w; L+ m7 ?5 }* C; {4 D' v7 Y0 a4 bApproximately 170,000 doses of the Canada's H1N1 vaccine were pulled from clinics across the country today after Manitoba health officials reported higher than normal allergic reactions to one batch.
; u1 j& x% C$ u6 x" {
The vaccine, manufactured in Ontario by GlaxoSmithKline, was distributed amongst several provinces. Of the 170,000 doses in the batch, 1500 were sent to Ontario clinics, but were not yet opened. GSK asked all provinces to set aside the doses from that batch as a precaution. In a written statement today, the company said, "GSK is taking this cautionary action because the Public Health Agency of Canada has received a higher than expected number of reports of anaphylaxis in this lot number compared to other lots."
/ @+ Q6 D; ?# S# ^7 G: y9 A
; N, N7 y1 P2 I1 I9 g" g: f3 hTypical batches of the vaccine see 1 to 2 severe reactions, but the batch in question had 6. All patients were treated at the scene for symptoms of anaphylaxis and are now doing fine. While mild side effects such as nausea, soreness, headaches or fever have been reported with the H1N1 vaccine, much like seasonal flu shots can cause, the anaphylaxis reactions were considered extreme.
2 j3 \( M; j; F+ [6 n
Canada's Chief Public Health Officer, Dr. David Butler-Jones reported earlier this week that of the 6.6 million H1N1 vaccinations that have been administered across the country, only 36 severe reactions had been reported. He reminded Canadians that reactions are rare, and the benefits of the H1N1 vaccine far outweigh the risks.

vilna

也不知这么大一家公司检验怎么过关的，生产量大了的原因？

vilna

华盛顿邮报
/ X. ~5 i1 K* Z+ t  {     
' Y( @* p6 f! l; ^( t  q     葛兰素史克公司(GSK)日前证实，由该公司提供的甲型H1N1流感疫苗在加拿大接种期间，已造成6人出现严重的过敏性休克反应，由于此类副作用发生率远远超过预期，因此同一批次的疫苗全部被紧急召回。据悉，这些问题疫苗共有17.2万剂，大部分已被注射到人体内。

　　葛兰素史克公司是唯一一家向加拿大人供应疫苗的企业，截止到11月13日，约750万剂葛兰素史克生产的甲型H1N1疫苗被发送到加拿大。不过，除加拿大外，这家公司生产的甲型H1N1流感疫苗在其他国家没有出现类似过敏反应案例。有关方面正在共同调查加拿大人对疫苗“过敏”的原因。自今年4月以来，全球约有6750人死于甲流。葛兰素史克公司此前称，从本季度到明年计划出厂4.5亿到5亿支 H1N1流感疫苗。目前，还不清楚此次严重过敏事件是否会对这家公司的后续疫苗销售产生影响。加拿大卫生官员提醒人们不必恐慌，并且强调接种疫苗后会出现短暂过敏反应，但反应持续时间通常不长且不会导致长期疾病。世卫组织也建议，人们应该继续接种甲型H1N1流感疫苗，因为现阶段疫苗“是最有效的抗击甲型H1N1流感疫情蔓延的途径”。共有8000万剂甲流疫苗被运往40个国家。世界卫生组织统计数字显示，全球只有30名接种者在接种甲流疫苗后死亡，但死亡原因与接种疫苗“没有直接联系”。截止目前，接种了此类疫苗的人数已经超过6500万。对加拿大来说，接种疫苗后的发生副作用的比例高达“万分之一”。其中，严重副作用(包括死亡在内)比例高达5%，其比例之高，已经超过了美国1976年流感疫苗。 (高轶军)

awake

我认识的人有质疑，为什么加拿大的疫苗只有一家生产厂提供，是否权钱交易的结果。

vilna

我认识的人有质疑，为什么加拿大的疫苗只有一家生产厂提供，是否权钱交易的结果。
6 T8 M* L2 H2 G/ ~; F. Eawake 发表于 2009-11-28 22:37

0 I# _. O# ^5 Q% ~/ f8 _& W6 o不知他们怎么定的决策